Associate Professor Joseph Mathew
Associate Professor Joseph Mathew currently serves as the Deputy Director of Alfred Health Trauma Services and Head of International Programs (South Asia) at the National Trauma Research Institute. Across his career, he has been successfully involved in the development of trauma systems throughout Asia, including India, Sri Lanka, China, and Saudi Arabia, including being the Australian lead of the successfully completed Australia-India Trauma System Collaboration.
As an adjunct professor at Deakin University, A/Prof Mathew’s interest areas include artificial intelligence and decision-making tools in medical assessment and treatment in emergent conditions with a special interest in trauma resuscitation. A/Prof Mathew also is working on remote monitoring systems for disease prediction and early intervention and has a special interest in aligning artificial intelligence with clinical gestalt. He recently co-created the successful AI-backed Pandemic Intervention and Monitoring System (PIMS) for remote monitoring of COVID-19. He has been a co-creator of successful mobility app systems for prehospital and trauma rehabilitation patients. He is currently developing various life-saving technologies, using nanotechnology for hemorrhage control and early bone healing.
A/Prof Mathew has been the founder and co-creator of multiple trauma educational programs including the highly successful cadaveric Trauma Procedures course, Emergency Trauma Management course, and the Trauma Team Training Program.
A/Prof Mathew is the Chair of the ARC Industrial Hub for Digital Enhanced Living and has previously chaired the Trauma subcommittee in the Australian College of Emergency Medicine. He is also a reviewer for multiple medical journals and has been a consultant to the Government of India and the Emirate of Abu Dhabi for the institution of trauma systems.
What does Scale Facilitation®
mean to you?
"Scale Facilitation® offers clinician inventors the ability to translate original innovations developed at the clinical coalface and scale up these innovations to achieve the best outcomes possible primarily for the patients and for the economy in comparison to the existing research funding pools where translation to clinical outcomes and to scale has been suboptimal."